Texas Instruments Incorporated vs Zimmer Biomet Holdings Inc — how do they compare? Texas Instruments Incorporated trades at $284.01 (market cap $256.84B), while Zimmer Biomet Holdings Inc trades at $97.27 (market cap $18.55B). The key difference: Texas Instruments Incorporated is far larger — about 13.8× Zimmer Biomet Holdings Inc's market cap, and Texas Instruments Incorporated pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| TXN | ZBH | |
|---|---|---|
Market Cap | $256.84B | $18.55B |
Sector | Technology | Health |
52-Week High | $332.35 | $107.71 |
52-Week Low | $153.33 | $79.58 |
Enterprise Value | $263.89B | $25.61B |
Dividend Yield | 2.02% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Texas Instruments (TXN) trades at $281.24, down 1.69% over 24 hours, with a bullish technical signal from moving averages and recent price action above the 20-day average. Revenue grew to $17.68 billion in 2025, with net income of $5.00 billion and strong profitability margins. Recent news highlights CFO transition and AI-driven demand boosting data center revenue.
Outlook remains positive with analyst consensus price target of $333.10, implying 18% upside. Risks include high valuation multiples and increasing debt-to-asset ratio. The stock presents opportunity from AI infrastructure growth but faces margin pressure and competitive threats.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →